Report Adverse Event or Product Quality Complaint   US Site   Global Site             

Header Logo
  • Prescribing Information
  • Therapy areas
    • All Therapeutic Areas
    • Cardiovascular, Renal and Metabolism
    • Immunology
    • Infection
    • Oncology
    • Rare Disease (Alexion)
    • Respiratory
  • Disease Education
  • Resources
    • Congress Library
    • Clinical Trials
    • Continuing Education
    • Patient Support
    • Pipeline
  • Connect
    • Connect with an MSL
    • Connect with an MSL
    • Submit an MIR
    • Give Feedback

Search Medical Information

Login

Request a field medical follow-up

  • Home
  • Congress Library
  • ESC-HF HFA 2025

Heart Failure Association - Heart Failure (ESC-HF HFA) - 2025

May 17 - 20, 2025

  1. All
  2. Forxiga (dapagliflozin)
  3. Heart Failure/Chronic Kidney Disease
  4. ATTR amyloidosis
  5. Sodium Zirconium Cyclosilicate

HTML

Relative and absolute benefit of dapagliflozin using different eGFR estimates: insights from DAPA-HF trial

PDF

Dapagliflozin for HFrEF: early experience of treatment adherence and impact on patient-reported outcomes in EVOLUTION HF, a multinational, observational study

PDF

Real-world burden of heart failure with reduced ejection fraction and dapagliflozin use at 2 years after approval in 9 countries from Central Eastern Europe and Baltic Area: EVOLUTION-HF CEE-BA study

SOdium-Glucose cotransporter 2 inhibitor with and without an ALDosterone AntagonIst for heart failure with Preserved Ejection Fraction: the SOGALDI-PEF trial

PDF

Cardiorenal pathways and characteristics of patients with coexisting heart failure and chronic kidney disease (The CaRe Study)

PDF

Treatment patterns and clinical outcomes following diagnosis in patients with ATTR amyloidosis – results from the OverTTuRe study

PDF

Early clinical manifestations and time-to-diagnosis in patients with ATTR amyloidosis with mixed phenotype – results from the OverTTuRe study

PDF

Sodium zirconium cyclosilicate, hyperkalaemia, and spironolactone optimisation in heart failure with reduced ejection fraction: the REALIZE-K open-label run-In phase

HTML

Relative and absolute benefit of dapagliflozin using different eGFR estimates: insights from DAPA-HF trial

PDF

Dapagliflozin for HFrEF: early experience of treatment adherence and impact on patient-reported outcomes in EVOLUTION HF, a multinational, observational study

PDF

Real-world burden of heart failure with reduced ejection fraction and dapagliflozin use at 2 years after approval in 9 countries from Central Eastern Europe and Baltic Area: EVOLUTION-HF CEE-BA study

SOdium-Glucose cotransporter 2 inhibitor with and without an ALDosterone AntagonIst for heart failure with Preserved Ejection Fraction: the SOGALDI-PEF trial

PDF

Cardiorenal pathways and characteristics of patients with coexisting heart failure and chronic kidney disease (The CaRe Study)

PDF

Treatment patterns and clinical outcomes following diagnosis in patients with ATTR amyloidosis – results from the OverTTuRe study

PDF

Early clinical manifestations and time-to-diagnosis in patients with ATTR amyloidosis with mixed phenotype – results from the OverTTuRe study

PDF

Sodium zirconium cyclosilicate, hyperkalaemia, and spironolactone optimisation in heart failure with reduced ejection fraction: the REALIZE-K open-label run-In phase

Disclaimer

Some content may have changed since publication. Some links may require registration/login to access the content. Any attached publications and/or any tables or figures derived from the publications are copyright-protected works. AstraZeneca has obtained permission from the copyright owner to use this work on this site. You may not reproduce, prepare derivative works from, display or distribute this work unless you obtain the permission of the copyright owner, or as otherwise might be permitted by law.

Connessiallasalute.it

This site is intended for healthcare professionals practicing in the US.
©2026 AstraZeneca. All rights reserved.

US-107328
Last Updated 3/26

Contact Us

About Us

AstraZeneca-US.com

Grant Opportunities  

Survey Feedback

Your Privacy Choice

Consumer Health Data 
Privacy Notice

Privacy Notice | Legal Notice | Cookie Preferences

Welcome to AstraZeneca Medical Information

The information provided on this site is intended for use by healthcare professionals practicing in the US. The dissemination of this information may be subject to different medical and regulatory requirements in other countries.

 

This web site is intended to help healthcare professionals practicing in the US and AstraZeneca authorized persons find scientifically balanced, evidence-based information about AstraZeneca drugs, submit a question, ask for field medical follow-up, and explore links to professional and patient support resources.

 

Are you a healthcare professional practicing in the United States?

I am an AstraZeneca authorized person   What is an AstraZeneca authorized person?
This website is only intended for healthcare professionals practicing in the United States and authorized AstraZeneca personnel. AstraZeneca US Headquarters personnel and US Field Medical personnel are authorized to browse and search the database for their own background knowledge and insight. US Field Sales personnel should not access or browse this site. None of the content of this site should be directly linked or distributed without approval.
I am not a healthcare professional practicing in the United States